Hangzhou Minsheng Binjiang Pharmaceutical CO., Ltd DMF, CEP, Written Confirmations, FDF, Prices, Patents, Patents & Exclusivities, Dossier, Manufacturer, Licensing, Distributer, Suppliers, News, GMP

Related Companies

Minsheng Group Hangzhou Minsheng Pharmaceutical Co., Ltd was established in 1926, which is one of the earliest four chemical pharmaceutical factories in China. The company has been specializing in the pharmaceutical industry since 1926, witnessed the entire history of western medicine in China. It is a large key enterprise and one of top 50 in national pharmaceutical industry. In 2006, It was honored as one of the firstly appr...

Minsheng Group Hangzhou Minsheng Pharmaceutical Co., Ltd was established in 1926, which is one of the earliest four chemical pharmaceutical factories in China. The company has been specializing in the pharmaceutical industry since 1926, witnessed the entire history of western medicine in China. It is a large key enterprise and one of top 50 in national pharmaceutical industry. In 2006, It was honored as one of the firstly approved "China's Time - honored Brand "Enterprises by commerce Department . The company produces four categories of products, that is prescription drugs (including anti-cancer, anti-hepatitis, cardiovascular drugs), OTC (multi-vitamin products and healthcare products), large valume parenterals (including special parenterals) and active pharmaceutical ingredients. 21 Super-Vita was recognized as a “Chinese Well-known Brand” in 2004, which makes it to be the leading multi-vitamin supplementary brand in China. The company has high prestige in anti-cancer drugs and large valume parenterals. The company has advanced quality system. All of the products and facilities have GMP certificates issued by SFDA. Meanwhile, the company was recognized as high-tech enterprise of developing and producing highly effective chemistry raw materials and kinds of formulations by the Hangzhou municipal government department concerned. APIs and intermediates are produced in Shaoxing facility, and six APIs have got FDA approval. The headquater covers an area of 190,000M2 in Hangzhou. There are nealy 3000 staffs, in which 20% are technicians. The Annual output of tablets is over 6 billion tablets. There are 4 advanced non-PVC L.V. parenterals production lines, of which the total capacity is over 60 million bags. The company invested 1200 million RMB to newly build the cGMP solid dosage production base, that is Minsheng Pharma. Binjiang Branch. Since 2003, the annual sales is over 1 billion RMB. After more than 80 years of accumulation and development, the company becomes to be an extremely professional and responsible modernized pharmaceutical company. The company implemented the leaping development strategy successfully from 2002 to 2006. Since 2007. the company has been fully implementing the international strategy, which leads the company to march for new success. To create a century Minsheng with enduring, endless and full of youthful vigor is our pursuit. Brief Introduction of Binjiang Branch Minsheng Pharma. Binjiang Branch (hereinafter called MSB) is located in Hangzhou Binjiang Hi-Tech Industry Development Zone, with convenient transportation, half hour by car from plant to Hangzhou international airport or railway station. The capital of the first phase is above RMB120 million. The total plant area is 30,000 m2 and the area of the first phase is 7,000㎡, including the cleaning area of 3200 m2. We mainly develop, manufacture and export generic drugs to the regulated markets especially US and EU. Strictly compliance with US FDA cGMP regulations, MSB is designed by an Australia company --- S2F and constructed by installments. At present, it has an advanced oral solid dosage production line with its annual production capacity about 250 milliontablets per shift which can be easily expended to 750 million by adding an another production line in current cleaning area. It also has a modern QC lab and “three wastes” treatment system. There are 45 staffs in MSB,in which over 80% have college degree，60% are technicians, and most have more than 5 years professional experience. There are 33% staffs involved quality work. MSB has established relatively perfect quality system according to US cGMP standard. MSB has developed four generic drugs including K001, developed in US, which ANDA has been approved. MSB passed GMP in china smoothly in Jan., 2010, and will receive a site inspectio by US FDA in the second half of 2010. Our aim is to provide overall solutions from R&D to production for our customers with high quality and competitive price

Company profile for Hangzhou Minsheng Binjiang Pharmaceutical CO., Ltd

Hangzhou Minsheng Binjiang Pharmaceutical CO., Ltd

HANGZHOU MINSHENG BINJIANG PHARMACEUTICAL CO., LTD

About

Contact Details

EVENTS

Webinars & Exhibitions

PRESENTATION(s)

VIDEO(s)

DIGITAL CONTENT

APIs // Active Pharmaceutical Ingredients

8 APIs

5 USDMF

3 CEP/COS

2 JDMF

12 NDC API

DEVELOPMENTS

DOSSIERs // Finished Dosage Formulations

5 Dossiers

5 FDA Orange Book

INSPECTIONS & REGISTRATIONS

3 FDA

2 GDUFA

What are you looking for?